Active Ingredient History

  • Now
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.   Wikipedia

  • SMILES: CC(C)(C)[C@@H]1NC(=O)OCC(C)(C)CCCCc2cccc3CN(Cc23)C(=O)O[C@@H]4C[C@H](N(C4)C1=O)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6
  • Mol. Mass: 755.93
  • ALogP: 3.67
  • ChEMBL Molecule:
More Chemistry
mk7009 | mk 7009 | mk-7009 | vanihep | vaniprevir


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue